Additional newer drugs also target angiogenesis, which include aflibercept, a vascular endothelial growth factor (VEGF) and placental growth factor (PIGF)-antagonist, and regorafenib, a multi-tyrosine kinase inhibitor, and have been shown to significantly improve the progression-free survival of CRC in Phase III randomized trials [6,7,8]. The gene discussed is VEGFA; the disease is colorectal carcinoma.